Samrat Pharmachem Ltd Stock Price Today (NSE: SAMRATPH)
Fundamental Score
Samrat Pharmachem Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Samrat Pharmachem Ltd share price today is ₹205.75, up +0.00% on NSE/BSE as of 18 February 2026. Samrat Pharmachem Ltd (SAMRATPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹75.79 (Cr). The 52-week high for SAMRATPH share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 48.58x, SAMRATPH is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 10.07% and a debt-to-equity ratio of 0.15.
Samrat Pharmachem Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Samrat Pharmachem Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Samrat Pharmachem Share Price: A Financial Snapshot and Growth Strategy Considerations
The pharmaceutical industry is currently undergoing a dynamic shift, with a growing emphasis on APIs (Active Pharmaceutical Ingredients) and strategic backward integration. This creates opportunities for companies positioned within the value chain. This analysis examines the current financial standing of Samrat Pharmachem share price, trading at ₹230.30, within this evolving landscape. This is part of a larger, 80-parameter fundamental audit, verified by Sweta Mishra, and is purely observational; it does not constitute investment advice.
With a PE ratio of 48.58, Samrat Pharmachem's valuation appears relatively high compared to the broader market. This suggests that investors anticipate future growth. However, when benchmarked against peers like
Mankind Pharma Ltd, a detailed evaluation of management quality is crucial. While Mankind Pharma boasts a strong track record of execution and capital allocation, Samrat Pharmachem needs to demonstrate comparable operational efficiency and strategic foresight to justify its premium valuation. This difference in perception of management capability contributes to stock valuations, alongside financial metrics.One key metric to consider is Samrat Pharmachem's Return on Capital Employed (ROCE) of 13.21%. ROCE signifies how efficiently a company uses its capital to generate profits. A consistent and growing ROCE contributes to building a sustainable competitive advantage, or 'moat'. In Samrat Pharmachem's case, a 13.21% ROCE indicates a reasonable level of profitability. However, maintaining and improving this figure is crucial for long-term value creation and potentially solidifying a stronger industry position. Continuous improvements in manufacturing processes, cost optimization, and strategic capacity expansion will be pivotal to enhance ROCE and strengthen the company's resilience.
Comparing Samrat Pharmachem to other sector peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, highlights the importance of a comprehensive competitive analysis. Understanding each company's specific product portfolio, market penetration strategies, and research and development investments is critical for assessing their individual growth prospects. Further, evaluating Samrat Pharmachem's debt levels and cash flow generation capabilities will provide a more complete picture of its financial health and its ability to fund future expansion. A thorough due diligence process is essential for discerning the true potential and risks associated with Samrat Pharmachem.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Samrat Pharmachem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAMRATPH across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Consistent Growth Track Record (15.77% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.15)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 48.58x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-122.18%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 3.24%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Samrat Pharmachem Ltd Financial Statements
Comprehensive financial data for Samrat Pharmachem Ltd including income statement, balance sheet and cash flow
About SAMRATPH (Samrat Pharmachem Ltd)
Samrat Pharmachem Ltd (SAMRATPH) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹75.79 (Cr). Samrat Pharmachem Ltd has delivered a Return on Equity (ROE) of 10.07% and a ROCE of 13.21%. The debt-to-equity ratio stands at 0.15, reflecting the company's capital structure. Investors tracking SAMRATPH share price can monitor key metrics including P/E ratio, promoter holding of 49.09%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
SAMRATPH Share Price: Frequently Asked Questions
What is the current share price of Samrat Pharmachem Ltd (SAMRATPH)?
As of 18 Feb 2026, 10:41 am IST, Samrat Pharmachem Ltd share price is ₹205.75. The SAMRATPH stock has a market capitalisation of ₹75.79 (Cr) on NSE/BSE.
Is SAMRATPH share price Overvalued or Undervalued?
SAMRATPH share price is currently trading at a P/E ratio of 48.58x, compared to the industry average of 31.77x. Based on this relative valuation, the Samrat Pharmachem Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SAMRATPH share price?
The 52-week high of SAMRATPH share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Samrat Pharmachem Ltd share price?
Key factors influencing SAMRATPH share price include quarterly earnings growth (Sales Growth: 12.40%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Samrat Pharmachem Ltd a good stock for long-term investment?
Samrat Pharmachem Ltd shows a 5-year Profit Growth of 10.15% and an ROE of 10.07%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.15 before investing in SAMRATPH shares.
How does Samrat Pharmachem Ltd compare with its industry peers?
Samrat Pharmachem Ltd competes with major peers in the Pharmaceuticals. Investors should compare SAMRATPH share price P/E of 48.58x and ROE of 10.07% against the industry averages to determine competitive standing.
What is the P/E ratio of SAMRATPH and what does it mean?
SAMRATPH share price has a P/E ratio of 48.58x compared to the industry average of 31.77x. Investors pay ₹49 for every ₹1 of annual earnings.
How is SAMRATPH performing according to Bull Run's analysis?
SAMRATPH has a Bull Run fundamental score of 38.1/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SAMRATPH belong to?
SAMRATPH operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Samrat Pharmachem Ltd share price.
What is Return on Equity (ROE) and why is it important for SAMRATPH?
SAMRATPH has an ROE of 10.07%, which shows decent profitability but room for improvement. ROE measures how efficiently Samrat Pharmachem Ltd generates profits from shareholders capital.
How is SAMRATPH debt-to-equity ratio and what does it indicate?
SAMRATPH has a debt-to-equity ratio of 0.15, which indicates conservative financing with low financial risk.
What is SAMRATPH dividend yield and is it a good dividend stock?
SAMRATPH offers a dividend yield of 0.41%, meaning you receive ₹0.41 annual dividend for every ₹100 invested in Samrat Pharmachem Ltd shares.
How has SAMRATPH share price grown over the past 5 years?
SAMRATPH has achieved 5-year growth rates of: Sales Growth 15.77%, Profit Growth 10.15%, and EPS Growth 10.15%.
What is the promoter holding in SAMRATPH and why does it matter?
Promoters hold 49.09% of SAMRATPH shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Samrat Pharmachem Ltd.
What is SAMRATPH market capitalisation category?
SAMRATPH has a market capitalisation of ₹76 crores, placing it in the Small-cap category.
How volatile is SAMRATPH stock?
SAMRATPH has a beta of N/A. A beta > 1 suggests the Samrat Pharmachem Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SAMRATPH operating profit margin trend?
SAMRATPH has a 5-year average Operating Profit Margin (OPM) of 5.45%, indicating the company's operational efficiency.
How is SAMRATPH quarterly performance?
Recent quarterly performance shows Samrat Pharmachem Ltd YoY Sales Growth of 12.40% and YoY Profit Growth of -122.18%.
What is the institutional holding pattern in SAMRATPH?
SAMRATPH has FII holding of 3.24% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Samrat Pharmachem Ltd stock.